Table 1.
A summary of patient and tumor characteristics of the study population.
| Variables |
All retrospective patients (n = 479) |
Training cohort (n = 359) |
Testing cohort (n = 120) |
P-value |
Prospective cohort (n = 16) |
P-value |
|---|---|---|---|---|---|---|
| Age (mean ± SD) | 48.7 ± 11.1 | 48.9 ± 10.9 | 47.9 ± 11.9 | 0.844 | 49.8 ± 11.3 | 0.680 |
| Histological grade | 0.755 | 0.556 | ||||
| I | 187 (39.0%) | 140 (39.0%) | 47 (39.2%) | 8 (50.0%) | ||
| II | 249 (52.0%) | 190 (52.9%) | 59 (49.2%) | 7 (43.7%) | ||
| III | 43 (9.0%) | 29 (8.1%) | 14 (11.6%) | 1 (6.3%) | ||
| Molecular subtype | 0.457 | - | - | |||
| Luminal A | 45 (9.4%) | 33 (9.2%) | 12 (10.0%) | - | ||
| Luminal B | 322 (67.2%) | 239 (66.6%) | 83 (69.2%) | - | ||
| HER2 positive | 57 (11.9%) | 44 (12.3%) | 13 (10.8%) | - | ||
| Triple negative | 55 (11.5%) | 43 (11.9%) | 12 (10.0%) | - | ||
| ALN | 0.829 | 0.418 | ||||
| Positive | 136 (28.4%) | 101 (28.1%) | 35 (29.2%) | 6 (37.5%) | ||
| Negative | 343 (71.6%) | 258 (71.9%) | 85 (70.8%) | 10 (62.5%) |
P-values were calculated by using χ2 test or Wilcoxon rank-sum test. P-values in the fifth column were calculated between training and testing cohorts. P-values in the seventh column were calculated between training and prospective cohorts.